Across the past 12 months, open-market trades by Inhibikase Therapeutics insiders were all purchases, totaling $3 million (2.07Mn shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Capital Life Sciences Pulse Fund Ii, L.P. Sands | TenPercentOwner | 13,018,965 | 0 | 13,018,965 | 54.8% | 24 Nov, 2025 |
| 2 | Capital Management, L.P. Ra | TenPercentOwner | 0 | 6,970,000 | 6,970,000 | 29.4% | 31 Jul, 2026 |
| 3 | Roberto Bellini | Director | 0 | 1,460,000 | 1,460,000 | 6.2% | 23 Oct, 2024 |
| 4 | Milton H. Werner | President And Ceo | 889,257 | 0 | 889,257 | 3.7% | 16 Aug, 2022 |
| 5 | Christopher Cabell | President Head Of Rd | 676,564 | 0 | 676,564 | 2.9% | 24 Feb, 2026 |
| 6 | Vincent Aurentz | Director | 510,596 | 0 | 510,596 | 2.2% | 24 Feb, 2026 |
| 7 | Arvind Kush | Director | 145,000 | 0 | 145,000 | 0.6% | 23 Oct, 2024 |
| 8 | Amit Munshi | Director | 38,176 | 0 | 38,176 | 0.2% | 24 Feb, 2026 |
| 9 | Dennis N Berman | Director | 21,854 | 0 | 21,854 | 0.1% | 31 Jul, 2026 |
| 10 | Joseph Frattaroli | Chief Financial Officer | 8,015 | 0 | 8,015 | 0.0% | 23 May, 2022 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 29 Jul, 2026 | Capital Management, L.P. Ra | TenPercentOwner | Disposed J | 18,030,000 | — | — | 6,970,000 | Indirect |
| 30 Jul, 2026 | Dennis N Berman | Director | Acquired M | 21,854 | $1.26 | $27.54K | 21,854 | Direct |
| 30 Jul, 2026 | Dennis N Berman | Director | Disposed M | 21,854 | $0.00 | $0 | 0 | Direct |
| 29 Jul, 2026 | Capital Management, L.P. Ra | TenPercentOwner | Acquired J | 18,030,000 | — | — | 18,030,000 | Indirect |
| 26 Jun, 2026 | Roberto Bellini | Director | Acquired A | 155,000 | $0.00 | $0 | 155,000 | Direct |
| 26 Jun, 2026 | Vincent Aurentz | Director | Acquired A | 155,000 | $0.00 | $0 | 155,000 | Direct |
| 26 Jun, 2026 | Amit Munshi | Director | Acquired A | 155,000 | $0.00 | $0 | 155,000 | Direct |
| 26 Jun, 2026 | Dennis N Berman | Director | Acquired A | 155,000 | $0.00 | $0 | 155,000 | Direct |
| 26 Jun, 2026 | Arvind Kush | Director | Acquired A | 155,000 | $0.00 | $0 | 155,000 | Direct |
| 26 Jun, 2026 | David Canner | Director | Acquired A | 155,000 | $0.00 | $0 | 155,000 | Direct |
| 21 Feb, 2026 | Vincent Aurentz | Director | Disposed D | 255,299 | $0.00 | $0 | 510,596 | Direct |
| 21 Feb, 2026 | Christopher Cabell | President Head Of Rd | Disposed D | 338,282 | $0.00 | $0 | 676,564 | Direct |
| 21 Feb, 2026 | Amit Munshi | Director | Disposed D | 19,089 | $0.00 | $0 | 38,176 | Direct |
| 05 Jan, 2026 | Mark T Iwicki | Chief Executive Officer | Acquired A | 4,982,706 | $0.00 | $0 | 4,982,706 | Direct |
| 05 Jan, 2026 | David Mcintyre | Chief Financial Officer | Acquired A | 986,319 | $0.00 | $0 | 986,319 | Direct |
| 05 Jan, 2026 | Christopher Cabell | President Head Of Rd | Acquired A | 900,117 | $0.00 | $0 | 900,117 | Direct |
| 21 Nov, 2025 | Capital Life Sciences Pulse Fund Ii, L.P. Sands | TenPercentOwner | Acquired P | 2,068,965 | $1.45 | $3.00Mn | 13,018,965 | Direct |
| 30 Jun, 2025 | Amit Munshi | Director | Acquired A | 108,176 | $0.00 | $0 | 108,176 | Direct |
| 30 Jun, 2025 | Vincent Aurentz | Director | Acquired A | 108,176 | $0.00 | $0 | 108,176 | Direct |
| 30 Jun, 2025 | Dennis N Berman | Director | Acquired A | 108,176 | $0.00 | $0 | 108,176 | Direct |